Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in etiology.

Nielsen AB, Zhou M, de Smith AJ, Wang R, McCoy L, Hansen H, Morimoto L, Grønbæk K, Johansen C, Kogan SC, Metayer C, Bracci PM, Ma X, Wiemels JL.

Haematologica. 2019 Mar 28. pii: haematol.2019.216465. doi: 10.3324/haematol.2019.216465. [Epub ahead of print]

2.

Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia.

Gaillard C, Surianarayanan S, Bentley T, Warr MR, Fitch B, Geng H, Passegué E, de Thé H, Kogan SC.

Blood Adv. 2018 Oct 9;2(19):2462-2466. doi: 10.1182/bloodadvances.2018018929.

3.

Dilute Russell viper venom time interpretation and clinical correlation: A two-year retrospective institutional review.

Jacquot C, Wool GD, Kogan SC.

Int J Lab Hematol. 2019 Feb;41(1):80-86. doi: 10.1111/ijlh.12925. Epub 2018 Sep 8.

PMID:
30194751
4.

Severe Iron Metabolism Defects in Mice With Double Knockout of the Multicopper Ferroxidases Hephaestin and Ceruloplasmin.

Fuqua BK, Lu Y, Frazer DM, Darshan D, Wilkins SJ, Dunn L, Loguinov AV, Kogan SC, Matak P, Chen H, Dunaief JL, Vulpe CD, Anderson GJ.

Cell Mol Gastroenterol Hepatol. 2018 Jun 23;6(4):405-427. doi: 10.1016/j.jcmgh.2018.06.006. eCollection 2018.

5.

TCEA1 regulates the proliferative potential of mouse myeloid cells.

Yang T, Cui H, Wen M, Zuber J, Kogan SC, Wei G.

Exp Cell Res. 2018 Sep 15;370(2):551-560. doi: 10.1016/j.yexcr.2018.07.020. Epub 2018 Jul 25.

PMID:
30009791
6.

Age-Related Impaired Efficacy of Bone Marrow Cell Therapy for Myocardial Infarction Reflects a Decrease in B Lymphocytes.

An S, Wang X, Ruck MA, Rodriguez HJ, Kostyushev DS, Varga M, Luu E, Derakhshandeh R, Suchkov SV, Kogan SC, Hermiston ML, Springer ML.

Mol Ther. 2018 Jul 5;26(7):1685-1693. doi: 10.1016/j.ymthe.2018.05.015. Epub 2018 Jun 15.

7.

Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.

Voisset E, Moravcsik E, Stratford EW, Jaye A, Palgrave CJ, Hills RK, Salomoni P, Kogan SC, Solomon E, Grimwade D.

Blood. 2018 Feb 8;131(6):636-648. doi: 10.1182/blood-2017-07-794784. Epub 2017 Nov 30.

8.

Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPα as a common target of TRIB1 and PML/RARA.

Keeshan K, Vieugué P, Chaudhury S, Rishi L, Gaillard C, Liang L, Garcia E, Nakamura T, Omidvar N, Kogan SC.

Haematologica. 2016 Oct;101(10):1228-1236. Epub 2016 Jul 6.

9.

Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis.

Wong JC, Weinfurtner KM, Alzamora Mdel P, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen SC, Ho TT, Flach J, Reynaud D, Passegué E, Downing JR, Shannon K.

Elife. 2015 Jul 20;4. doi: 10.7554/eLife.07839.

10.

Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation.

Gaillard C, Tokuyasu TA, Rosen G, Sotzen J, Vitaliano-Prunier A, Roy R, Passegué E, de Thé H, Figueroa ME, Kogan SC.

Haematologica. 2015 Aug;100(8):1064-75. doi: 10.3324/haematol.2014.123018. Epub 2015 Jun 18.

11.

Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia.

Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, Lieber MR, Greaves MF, Müschen M.

Nat Immunol. 2015 Jul;16(7):766-774. doi: 10.1038/ni.3160. Epub 2015 May 18.

12.

Direct and indirect targeting of MYC to treat acute myeloid leukemia.

Brondfield S, Umesh S, Corella A, Zuber J, Rappaport AR, Gaillard C, Lowe SW, Goga A, Kogan SC.

Cancer Chemother Pharmacol. 2015 Jul;76(1):35-46. doi: 10.1007/s00280-015-2766-z. Epub 2015 May 9.

13.

Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis.

Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, Kogan SC, Lowe SW.

Nat Genet. 2015 May;47(5):539-43. doi: 10.1038/ng.3251. Epub 2015 Mar 30.

14.

Preclinical efficacy of MEK inhibition in Nras-mutant AML.

Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q.

Blood. 2014 Dec 18;124(26):3947-55. doi: 10.1182/blood-2014-05-574582. Epub 2014 Oct 31.

15.

Crenolanib is a selective type I pan-FLT3 inhibitor.

Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP.

Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5319-24. doi: 10.1073/pnas.1320661111. Epub 2014 Mar 12.

16.

CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression.

Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, LaBarge MA, You L, Kogan SC, Gray JW, Mao JH, Wei G.

Cancer Res. 2014 Jan 15;74(2):520-31. doi: 10.1158/0008-5472.CAN-13-2182. Epub 2013 Dec 4.

17.

Pten loss in the bone marrow leads to G-CSF-mediated HSC mobilization.

Tesio M, Oser GM, Baccelli I, Blanco-Bose W, Wu H, Göthert JR, Kogan SC, Trumpp A.

J Exp Med. 2013 Oct 21;210(11):2337-49. doi: 10.1084/jem.20122768. Epub 2013 Oct 14.

18.

The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia.

Arteaga MF, Mikesch JH, Qiu J, Christensen J, Helin K, Kogan SC, Dong S, So CW.

Cancer Cell. 2013 Mar 18;23(3):376-89. doi: 10.1016/j.ccr.2013.02.014.

19.

Initially disadvantaged, TEL-AML1 cells expand and initiate leukemia in response to irradiation and cooperating mutations.

Li M, Jones L, Gaillard C, Binnewies M, Ochoa R, Garcia E, Lam V, Wei G, Yang W, Lobe C, Hermiston M, Passegué E, Kogan SC.

Leukemia. 2013 Jul;27(7):1570-3. doi: 10.1038/leu.2013.15. Epub 2013 Jan 16. No abstract available.

20.

PML-RARα co-operates with Sox4 in acute myeloid leukemia development in mice.

Omidvar N, Maunakea ML, Jones L, Sevcikova S, Yin B, Himmel KL, Tennant TR, Le Beau MM, Largaespada DA, Kogan SC.

Haematologica. 2013 Mar;98(3):424-7. doi: 10.3324/haematol.2011.057067. Epub 2012 Nov 9.

21.

A dominantly acting murine allele of Mcm4 causes chromosomal abnormalities and promotes tumorigenesis.

Bagley BN, Keane TM, Maklakova VI, Marshall JG, Lester RA, Cancel MM, Paulsen AR, Bendzick LE, Been RA, Kogan SC, Cormier RT, Kendziorski C, Adams DJ, Collier LS.

PLoS Genet. 2012;8(11):e1003034. doi: 10.1371/journal.pgen.1003034. Epub 2012 Nov 1.

22.

An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model.

Bergerson RJ, Collier LS, Sarver AL, Been RA, Lugthart S, Diers MD, Zuber J, Rappaport AR, Nixon MJ, Silverstein KA, Fan D, Lamblin AF, Wolff L, Kersey JH, Delwel R, Lowe SW, O'Sullivan MG, Kogan SC, Adams DJ, Largaespada DA.

Blood. 2012 May 10;119(19):4512-23. doi: 10.1182/blood-2010-04-281428. Epub 2012 Mar 16.

23.

Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity.

Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, Kogan SC, Lowe SW.

Genes Dev. 2011 Oct 15;25(20):2125-36. doi: 10.1101/gad.17276711. Epub 2011 Oct 6.

24.

An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.

Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Taylor MJ, Weissenboeck M, Graeber TG, Kogan SC, Vakoc CR, Lowe SW.

Genes Dev. 2011 Aug 1;25(15):1628-40. doi: 10.1101/gad.17269211. Erratum in: Genes Dev. 2011 Sep 15;25(18):1997. Fellman, Christof [corrected to Fellmann, Christof].

25.

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR.

Nature. 2011 Aug 3;478(7370):524-8. doi: 10.1038/nature10334.

26.

Treatment with 5-azacytidine accelerates acute promyelocytic leukemia leukemogenesis in a transgenic mouse model.

Scaglioni PP, Cai LF, Majid SM, Yung TM, Socci ND, Kogan SC, Kopelovich L, Pandolfi PP.

Genes Cancer. 2011 Feb;2(2):160-5. doi: 10.1177/1947601911410300.

27.

PML-RARα enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway.

Huang Y, Hou JK, Chen TT, Zhao XY, Yan ZW, Zhang J, Yang J, Kogan SC, Chen GQ.

Autophagy. 2011 Oct;7(10):1132-44. doi: 10.4161/auto.7.10.16636. Epub 2011 Oct 1.

28.

A rapid and scalable system for studying gene function in mice using conditional RNA interference.

Premsrirut PK, Dow LE, Kim SY, Camiolo M, Malone CD, Miething C, Scuoppo C, Zuber J, Dickins RA, Kogan SC, Shroyer KR, Sordella R, Hannon GJ, Lowe SW.

Cell. 2011 Apr 1;145(1):145-58. doi: 10.1016/j.cell.2011.03.012.

29.

Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.

Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO, Shannon K.

Cancer Res. 2011 Jan 1;71(1):106-15. doi: 10.1158/0008-5472.CAN-10-2732.

30.

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K.

Blood. 2011 Feb 10;117(6):2022-32. doi: 10.1182/blood-2010-04-280750. Epub 2010 Dec 16.

31.

Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia.

Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A, Wong JC, Li M, Dubansky J, Maunakea ML, Ochoa R, Zhu G, Tennant TR, Shannon KM, Lowe SW, Le Beau MM, Kogan SC.

J Exp Med. 2010 Nov 22;207(12):2581-94. doi: 10.1084/jem.20091071. Epub 2010 Nov 8.

32.

PML-RAR{alpha} and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia.

Subramanyam D, Belair CD, Barry-Holson KQ, Lin H, Kogan SC, Passegué E, Blelloch R.

Cancer Res. 2010 Nov 1;70(21):8792-801. doi: 10.1158/0008-5472.CAN-08-4481. Epub 2010 Sep 21. Erratum in: Cancer Res. 2011 Apr 1;71(7):2805.

33.

p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.

Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW.

Genes Dev. 2010 Jul 1;24(13):1389-402. doi: 10.1101/gad.1940710.

34.

Medicine. Poisonous contacts.

Kogan SC.

Science. 2010 Apr 9;328(5975):184-5. doi: 10.1126/science.1189198. No abstract available.

PMID:
20378808
35.

Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies.

Wong JC, Zhang Y, Lieuw KH, Tran MT, Forgo E, Weinfurtner K, Alzamora P, Kogan SC, Akagi K, Wolff L, Le Beau MM, Killeen N, Shannon K.

Blood. 2010 Jun 3;115(22):4524-32. doi: 10.1182/blood-2009-07-232504. Epub 2010 Mar 16.

36.

Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.

Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, Braun BS, Shannon K.

Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5106-11. doi: 10.1073/pnas.1001064107. Epub 2010 Mar 1.

37.

Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.

Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, Diaz-Flores E, Gorman M, Przybranowski S, Tran M, Kogan SC, Roose JP, Copeland NG, Jenkins NA, Parada L, Wolff L, Sebolt-Leopold J, Shannon K.

Nature. 2009 Sep 17;461(7262):411-4. doi: 10.1038/nature08279. Epub 2009 Sep 2.

38.

Mouse models of human AML accurately predict chemotherapy response.

Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W, McCurrach ME, Yang MM, Dolan ME, Kogan SC, Downing JR, Lowe SW.

Genes Dev. 2009 Apr 1;23(7):877-89. doi: 10.1101/gad.1771409.

39.

Curing APL: differentiation or destruction?

Kogan SC.

Cancer Cell. 2009 Jan 6;15(1):7-8. doi: 10.1016/j.ccr.2008.12.012.

40.

mTORC1 promotes survival through translational control of Mcl-1.

Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, Trojahn U, Wendel HG, Charest A, Bronson RT, Kogan SC, Nadon R, Housman DE, Lowe SW, Pelletier J.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10853-8. doi: 10.1073/pnas.0804821105. Epub 2008 Jul 29.

41.

Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure.

Nagasubramanian R, Hansen RJ, Delaney SM, Cherian MM, Samson LD, Kogan SC, Dolan ME.

Mutagenesis. 2008 Sep;23(5):341-6. doi: 10.1093/mutage/gen018. Epub 2008 May 13.

42.

PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL.

Tabe Y, Konopleva M, Kondo Y, Contractor R, Tsao T, Konoplev S, Shi Y, Ling X, Watt JC, Tsutsumi-Ishii Y, Ohsaka A, Nagaoka I, Issa JP, Kogan SC, Andreeff M.

Cancer Biol Ther. 2007 Dec;6(12):1967-77. Epub 2007 Sep 4.

PMID:
18075297
43.

Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders.

Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J, Crispino JD, Le Beau MM.

Blood. 2007 Jul 15;110(2):719-26. Epub 2007 Apr 9.

44.

Mouse models of acute promyelocytic leukemia.

Kogan SC.

Curr Top Microbiol Immunol. 2007;313:3-29. Review.

PMID:
17217036
45.

Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice.

Lee BD, Sevcikova S, Kogan SC.

Leuk Res. 2007 Aug;31(8):1131-4. Epub 2006 Dec 20.

46.

Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice.

Kim A, Morgan K, Hasz DE, Wiesner SM, Lauchle JO, Geurts JL, Diers MD, Le DT, Kogan SC, Parada LF, Shannon K, Largaespada DA.

Blood. 2007 Feb 15;109(4):1687-91. Epub 2006 Nov 7.

47.

Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo.

Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, Pelletier J, Lowe SW.

Cancer Res. 2006 Aug 1;66(15):7639-46.

48.

CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities.

Lee YJ, Jones LC, Timchenko NA, Perrotti D, Tenen DG, Kogan SC.

Blood. 2006 Oct 1;108(7):2416-9. Epub 2006 Jun 20.

49.

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Wendel HG, de Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, Lowe SW.

Proc Natl Acad Sci U S A. 2006 May 9;103(19):7444-9. Epub 2006 May 1.

50.

Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia.

Yin B, Kogan SC, Dickins RA, Lowe SW, Largaespada DA.

Exp Hematol. 2006 May;34(5):631-41.

PMID:
16647569

Supplemental Content

Loading ...
Support Center